XOMA Royalty Corporation (NASDAQ:XOMA) Receives Consensus Recommendation of “Hold” from Brokerages

XOMA Royalty Corporation (NASDAQ:XOMA) has earned a consensus rating of “Hold” from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $60.60.

Several equities research analysts have commented on XOMA shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of XOMA Royalty in a research report on Monday, December 29th. Stifel Nicolaus set a $50.00 target price on shares of XOMA Royalty in a report on Friday, December 12th. Leerink Partners decreased their price target on shares of XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, December 11th. Zacks Research cut XOMA Royalty from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 18th. Finally, Wall Street Zen lowered XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th.

Insider Activity

In other news, CEO Owen Hughes acquired 100,000 shares of the stock in a transaction on Thursday, December 4th. The shares were purchased at an average cost of $25.05 per share, for a total transaction of $2,505,000.00. Following the transaction, the chief executive officer owned 102,000 shares in the company, valued at approximately $2,555,100. This trade represents a 5,000.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.20% of the stock is owned by corporate insiders.

Institutional Trading of XOMA Royalty

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in XOMA Royalty by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock worth $25,749,000 after buying an additional 29,298 shares during the period. Opaleye Management Inc. boosted its stake in XOMA Royalty by 0.8% during the second quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company’s stock worth $6,428,000 after buying an additional 2,044 shares in the last quarter. Woodline Partners LP boosted its stake in XOMA Royalty by 16.5% during the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock worth $8,091,000 after buying an additional 29,715 shares in the last quarter. Geode Capital Management LLC increased its holdings in XOMA Royalty by 9.1% in the 2nd quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after buying an additional 16,929 shares during the period. Finally, Stonepine Capital Management LLC raised its stake in shares of XOMA Royalty by 17.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock valued at $3,834,000 after buying an additional 22,330 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Royalty Stock Up 5.3%

XOMA stock opened at $27.99 on Monday. The firm’s 50-day moving average is $30.26 and its two-hundred day moving average is $31.18. The company has a market capitalization of $346.52 million, a price-to-earnings ratio of 37.82 and a beta of 0.89. XOMA Royalty has a 52 week low of $18.35 and a 52 week high of $39.92. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07.

XOMA Royalty (NASDAQ:XOMA) last released its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%.The firm had revenue of $9.35 million during the quarter, compared to analyst estimates of $11.47 million. On average, analysts forecast that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.